成都看好下肢静脉曲张费用多少(成都怎么样治婴儿血管瘤) (今日更新中)

WASHINGTON, April 19 (Xinhua) -- The U.S. National Aeronautics and Space Administration (NASA) on Tuesday set April 29 as the launch date for Endeavour's final voyage.The date was announced Tuesday at the conclusion of a flight readiness review at Kennedy Space Center. During the meeting, senior NASA and contractor managers assessed the risks associated with the mission and determined the shuttle and station's equipment, support systems and personnel are ready.Liftoff time is 3:47 p.m. EDT (1947 GMT). It will be the 134th shuttle mission overall, the 25th for Endeavour and the 36th shuttle mission to the International Space Station.Endeavour will deliver to the station a 2-billion-dollar, multinational particle detector known as the Alpha Magnetic Spectrometer.Space shuttle Endeavour sits on launch pad 39A with the crew aboard minutes before mission managers scrubbed the launch again at Cape Canaveral, Florida, July 13, 2009.The spectrometer, also designated AMS-02, is a particle physics experiment module that is to be mounted on the station. It is designed to search for various types of unusual matter by measuring cosmic rays. Its experiments will help researchers study the formation of the Universe and search for evidence of dark matter and antimatter.Endeavour's two-week mission was led by Commander Mark Kelly. Other crew include Pilot Greg Johnson, NASA Mission Specialists Michael Fincke, Andrew Feustel and Greg Chamitoff and European Space Agency Mission Specialist Roberto Vittori. Astronauts are planning to step out on four spacewalks to do maintenance work and install new components.NASA's 30-year-old shuttle program is ending this year due to high operating costs. The Obama administration wants to spur private companies to get into the space taxi business, freeing NASA to focus on deep space exploration and new technology development.Shuttle Atlantis is set for its final journey into space at the end of June. Its return to earth will mark the official end of the U.S. space shuttle program. After that, the Russian space program' s Soyuz capsule will be the only method for transporting astronauts to and from the station.

LOS ANGELES, April 11 (Xinhua) -- Drinking 100-percent fruit juice may offer disease-fighting benefits, a new study suggests.Fruit juice is linked with reduced risk of cancer, improved markers of heart health and cognitive decline, and increased antioxidant activity, according to the study published on Monday by the American Association for the Advancement of Science (AAAS).These protective health benefits are similar to those of whole fruits, said the study, conducted by researchers at the University of California, Davis.The researchers came to the conclusion after summarizing recent research data on the potential benefits of fruit juice. The review included a range of study types, from in vitro to clinical trials (60 papers total), all published in 2005 or later.Among the fruit juices included in the review, consumption of apple, citrus, cranberry, grape, and pomegranate juices all showed beneficial effects. Markers of improved health ranged from reductions in urinary tract infections (cranberry) to improvements in age-related cognitive decline (grape and apple) to reduced risk of prostate (pomegranate) and respiratory and digestive (orange, grapefruit) cancers. Additionally, intake of all juices was linked to heightened antioxidant activity."While it is universally accepted that fruit and vegetable intake is protective, there is not a clear consensus about the benefits of consuming the juices that are extracted from them," said study lead author Dianne Hyson, PhD. "An analysis of the scientific evidence suggests that 100 percent fruit juices retain important bioactive components that may promote good health and aid in disease prevention."

SAN FRANCISCO, May 3 (Xinhua) -- Microsoft announced on Tuesday that its Bing search engine will become the default search and mapping application on Blackberry phones.Microsoft Chief Executive Officer Steve Ballmer announced the partnership with Research in Motion (RIM), which makes Blackberry phones, at the Blackberry World Conference in Orlando, Florida, according to a Microsoft blog post.Ballmer said Microsoft would invest uniquely in the Blackberry platform in addition to its own Windows Phone platform."Bing will be deeply integrated at the BlackBerry OS (operating system) level," Ballmer said.Central to the collaboration, Blackberry devices will use Bing as the preferred search provider in the browser, and Bing will be the default search and map application for new devices presented to mobile operators, both in the United States and internationally, said Microsoft's Bing team in the blog post.Meanwhile, Bing is also shipping as the default search experience and map application for the newly released Blackberry Playbook, a RIM tablet computer which made market debut on April 19.On Tuesday's Blackberry conference, Ballmer called Google's Android ecosystem "chaos" and the Apple iOS "limited" before he hailed Windows Phone 7 and Blackberry. Microsoft and RIM are both competing with Apple, which makes the iPhone and iPad, and Google, which makes the Android operating system for smartphones and tablets in the booming mobile device market.

WASHINGTON, April 25 (Xinhua) -- A class of drugs that shows promise in breast and ovarian cancers with BRCA gene mutations could potentially benefit colorectal cancer patients with a different genetic mutation, a new study from the University of Michigan Comprehensive Cancer Center finds.Working in cell lines from colorectal cancer patients, researchers found that the class of drugs called PARP inhibitors worked against tumors with mutations in the MRE11 gene.About 15 percent of all colorectal cancers have what's called microsatellite instability, a type of error in the DNA. About 82 percent of those tumors have the MRE11 gene mutation."This is a potential broader application for PARP inhibitors, beyond breast and ovarian cancer. This is a class of drug that's already shown safety in early clinical trials and now might benefit some colorectal cancer patients as well," says lead study author Eduardo Vilar-Sanchez, a hematology/oncology fellow at the university, in a statement.The study, which was published Monday in Cancer Research, also found that PARP inhibitors are even more effective when both copies of MRE11 were mutated. Each person carries two copies of each gene, which means mutations can occur in either one or both copies. The researchers suggest that PARP inhibitors could be targeted specifically to colorectal cancer patients who have two copies of the mutated gene.Researchers are planning a phase I clinical trial to look at using PARP inhibitors in colorectal cancer patients with two mutated copies of MRE11. Future trials are being considered using PARP inhibitors to prevent colorectal cancer and other cancers in people with Lynch syndrome whose tumors have this mutation.Microsatellite instability is also seen in prostate cancer and endometrial cancer, suggesting potential for PARP inhibitors to play a role in additional types of cancer as well, Vilar-Sanchez says, adding that more research is needed in these areas.

来源：资阳报